Scoliosis Treatment Market Summary
As per MRFR Analysis, the Global Scoliosis Treatment Market was valued at USD 165.2 Billion in 2023 and is projected to reach USD 407.9 Billion by 2032, growing at a CAGR of 11.40% from 2024 to 2032. The market growth is driven by advancements in treatment options and an increasing prevalence of scoliosis among children and adults. Notable innovations include the MARVELTM Growing Rod System by Globus Medical, aimed at treating early-onset scoliosis, and NGENLA, a new growth hormone treatment by Pfizer for pediatric patients. The adolescent idiopathic scoliosis segment leads the market, accounting for 65% of revenue, while hospitals and clinics are the primary distribution channels, generating the most income.
Key Market Trends & Highlights
The scoliosis treatment market is witnessing significant growth due to various factors.
- Market Size in 2023: USD 165.2 Billion
- Projected Market Size by 2032: USD 407.9 Billion
- CAGR from 2024 to 2032: 11.40%
- Adolescent idiopathic scoliosis segment accounts for 65% of market revenue
Market Size & Forecast
2023 Market Size: USD 165.2 Billion
2024 Market Size: USD 171.9 Billion
2032 Market Size: USD 407.9 Billion
CAGR (2024-2032): 11.40%
Major Players
Key players include Zimmer Biomet, Globus Medical, Pfizer Inc., and Spinal Technology Inc.
Source Secondary Research, Primary Research, MRFR Database and Analyst Review
In July 2023, Globus Medical, Inc., a leading company in the market, introduced the MARVELTM Growing Rod System. This system is designed for children with early-onset scoliosis and enables both growth and correction using minimally invasive distraction techniques. The system is scheduled to be commercially accessible to patients in the imminent future. The MARVELTM growth rods include a durable gear mechanism that effectively and dependably extends the rods over a broad expansion range of 40 or 60 mm. Additionally, the rods' PEEK polymer bearing surfaces minimize wear. A minimally invasive technique is employed to extend each rod, wherein a small incision is made to provide access to the driver while limiting harm to the surrounding soft tissues. Early onset scoliosis is a challenging disorder for spine surgeons who treat children, since they must carefully balance the child's development with correcting the curvature of the spine.
In June 2023, Pfizer Inc. and OPKO Health Inc. announced that pediatric patients aged three and above, who suffer from growth failure due to inadequate secretion of natural growth hormone, can now be treated with NGENLA (somatrogon-ghla). NGENLA is a human growth hormone analog that is administered once a week. NGENLA is expected to receive approval for prescription in the United States in August 2023. We are delighted to introduce this advanced treatment to patients in the United States. For more than three decades, Pfizer has been committed to assisting those who suffer from growth hormone shortage. This commitment began with the introduction of a medication that has become the accepted and customary treatment. Our objective is to persist in assisting children afflicted with this uncommon condition of abnormal growth to achieve their maximum capabilities.
Scoliosis Treatment Market Trends
- Growing number of patients is driving the market growth
Market CAGR for scoliosis treatment is being driven by the rising number of patients. Â Scoliosis is a medical disease characterized by a bent spine or backbone to one side. Scoliosis is growing increasingly widespread worldwide, particularly among youngsters. This is frequently shortly before puberty when children have a growth surge. Every year, about 600,000 patients with scoliosis seek treatment from private doctors. Every year, around 30,000 youngsters are fitted with braces, according to estimates. According to the National Scoliosis Foundation, scoliosis affects around 2-3% of the US population or approximately 6-9 million people. In addition, women are eight times more likely than males to have a curvature requiring treatment.
The spinal abnormality might produce back pain that lasts longer, whether sitting, standing, or walking. Duchenne muscular dystrophy (DMD), the most common muscular dystrophy, is predicted to strike one in every 3,600-6,000 newborn men. Embryological abnormality of one or more vertebrae in infancy, as well as illnesses such as spinal cord trauma, spinal Bifida, and spinal muscular atrophy in infants and adults, enhance the requirement for external support such as braces to prevent scoliosis from worsening. Furthermore, more time spent in front of a screen and sitting in an improper position for an extended time would increase the frequency of scoliosis cases, boosting the demand for scoliosis braces. Most scoliosis patients are advised to wear a brace.
Businesses in this market are developing innovative solutions to assist those with scoliosis. New scoliosis brace innovations that make them more customized, thinner, lighter, and breathable are anticipated to improve scoliosis braces. Market participants also use key methods such as acquisitions, mergers, distribution arrangements, and new goods to enhance their product lines and get a larger market share. Both organic and inorganic growth techniques are driving the market. Thus, driving the Scoliosis Treatment market revenue.
Scoliosis Treatment Market Segment Insights
Scoliosis Treatment Disease Insights
The Scoliosis Treatment market segmentation, based on disease, includes infantile idiopathic scoliosis and adolescent idiopathic scoliosis. The adolescent idiopathic scoliosis segment dominated the market, accounting for 65% of market revenue. MISS (minimally invasive spine surgery) has several advantages. Patients with Mwith heal significantly quicker than those with surgeries and can resume normal activities in about six weeks. Minimally invasive spine operations have a substantially greater success rate than standard surgery. As a result, the preference for MISS is rapidly expanding. Significant advancements in navigation and imaging technologies, the availability of biologics and customizable implants, the refinement of operative techniques, and feasibility, most importantly, evidence of efficacy and safety compared to traditional approaches have heralded a shift towards minimally invasive surgical techniques in recent years.
Scoliosis Treatment Product Insights
The Scoliosis Treatment market segmentation, based on product, includes cervical, thoracic, lumbar sacral orthosis (CTLSO), thoracolumbosacral orthosis (TLSO) and lumbosacral orthosis (LSO). The cervical, thoracic, and lumbar sacral orthosis (CTLSO) segment dominated the market. The portable TLSO market will develop incrementally in the future years as the number of back fractures and injuries rises. Furthermore, the rise in motor vehicle accidents is a driving force for the expansion since surgeons and physicians prescribe wearing a body brace for a long period to support the back while limiting mobility. Furthermore, the early detection of spinal disorders has caused hospitals and clinics to reserve their therapy for basic care, causing patients to seek TLSO in greater numbers.
Scoliosis Treatment Distribution Channel Insights
The Scoliosis Treatment market segmentation is based on distribution channels, hospitals & clinics, retail pharmacies and online pharmacies. The hospitals & clinics generated the most income. Spinal fusion operations are mostly conducted in hospitals and ASCs, a major reason driving the hospital segment's rise. Furthermore, favorable reimbursement rules and an expanding patient pool are expected to accelerate segment expansion.
Figure 1 Scoliosis Treatment Market, by Distribution channel, 2022 & 2032 (USD Billion)
Source Secondary Research, Primary Research, MRFR Database and Analyst Review
Scoliosis Treatment Regional Insights
By region, the study provides market insights into North America, Europe, Asia-Pacific and the Rest of the World. The North American Scoliosis Treatment market will dominate this market; This condition is becoming more common due to variables such as improved healthcare infrastructure and higher public knowledge and prevalence in the community. For example, the Canadian Pain Task Force (CPTF) was established in 2019 to advise the federal government on improving the treatment and management of chronic pain, a condition affecting over 8 million Canadians.
Further, the major countries studied in the market report are The US, Canada, the UK, Italy, Spain, China, Japan, India, German, France, Australia, South Korea, and Brazil.
Figure 2 SCOLIOSIS TREATMENT MARKET SHARE BY REGION 2022 (USD Billion)
Source Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe's Scoliosis Treatment market accounts for the second-largest market share due to the low cost of bariatric surgery and the rise in the number of diabetes people. Furthermore, the German Scoliosis Treatment market dominated, while the UK Scoliosis Treatment market grew the fastest in Europe.
The Asia-Pacific Scoliosis Treatment Market is expected to grow fastest from 2023 to 2032. This is due to the rising number of clinical trials providing new therapy choices for spinal diseases. Furthermore, China's Scoliosis Treatment market had the highest market share, while India's Scoliosis Treatment market was the fastest expanding in the Asia-Pacific region.
Scoliosis Treatment Key Market Players & Competitive Insights
Leading market companies are extensively spending R&D on increasing their product lines, which will help the Scoliosis Treatment market grow even more. Important market developments include new product releases, contractual agreements, acquisitions and mergers, greater investments, and collaboration with other organizations. The Scoliosis Treatment industry must produce cost-effective merchandise to flourish and thrive in a more competitive and increasing market climate.
Manufacturing locally to reduce operating costs is an effective business strategy manufacturers use in the worldwide Scoliosis Treatment industry to serve clients and expand the market sector. The Scoliosis Treatment industry has provided some of the most important benefits recently. Major players in the Scoliosis Treatment market, including Zimmer Biomet, Spinal Technology Inc, and others, are attempting to increase market demand by investing in research and development operations.
The world's foremost provider of musculoskeletal healthcare, Zimmer Biomet, was established in 1927 and had its headquarters in Warsaw, Indiana. They develop, produce, and sell orthopedic reconstructive goods and products for sports medicine, biologics, extremities, and trauma, office-based technologies, spine, craniomaxillofacial, and thoracic procedures, dental implants, and associated surgical items. To speed up innovation, they work with healthcare specialists worldwide. Patients with ailments or injuries to the bones, joints, or supporting soft tissues are helped by our goods and treatments. In May 2019, The first spinal tether device, idiopathic scoliosis, has been authorized by the U.S. FDA for use in children and adolescents who have not responded to conservative treatment approaches, including external bracing. The Tether-Vertebral Body Tethering System is a medical device designed to treat growing children and adolescents whose spinal curvature is on the verge of or has already crossed the threshold at which surgical intervention is a possibility.
Spinal technology is the industry leader ly in designing and producing Spinal Orthoses for stabilizing, immobilizing, and correcting different spine anomalies. They proudly uphold proficiency in various tried-and-true scoliosis bracing procedures and use cutting-edge technology to treat every patient. Spinal technology has been relied upon for over 30 years by medical professionals worldwide for the evaluation of patient curvature, the blueprinting and design of each orthosis, and the x-ray evaluation of patients throughout their scoliosis journey.In May 2021, The world's top manufacturer of bespoke spinal orthoses, Spinal Technology Inc., and Vorum Research Corp., a pioneer in CAD/CAM techniques for the worldwide O&P industry, have announced their North American Preferred Partnership.
Key Companies in the Scoliosis Treatment market include
- Lawall Prosthetics and Orthotics
- Wilmington Orthotics & Prosthetics, Inc.
- Horton's Orthotics & Prosthetics
- Zimmer Biomet Holdings Inc.
Scoliosis Treatment Industry Developments
May 2023Â Globus Medical, Inc. announced that the REFLECTTM Scoliosis Correction System, the company's first humanitarian product, has received clearance from the US Food and Drug Administration. The REFLECTTM procedure is intended to treat young patients with increasing scoliosis while conserving mobility, maintaining stability, and enabling future regulated growth.
December2021Â According to a National Scoliosis Centre article, the Department of Paediatric Orthopaedics at Johns Hopkins University is doing clinical trials with Dysport to provide a novel treatment for scoliosis in children. Dysport relaxes certain muscles in the back that surround the scoliosis curve, allowing the spine to become more flexible. It is administered in two doses, four months apart.
Scoliosis Treatment Market Segmentation
Scoliosis Treatment Disease Outlook
- Infantile Idiopathic Scoliosis
- Adolescent Idiopathic Scoliosis
Scoliosis Treatment Product Outlook
- Cervical Thoracic Lumbar Sacral Orthosis (CTLSO)
- Thoracolumbosacral Orthosis (TLSO)
- Lumbosacral Orthosis (LSO)
Scoliosis Treatment Distribution Channel Outlook
Scoliosis Treatment Regional Outlook
Scoliosis Treatment Report Scope
| Report Attribute/Metric |
Details |
| Market Size 2023 |
USD 165.2 Billion |
| Market Size 2024 |
USD 171.9 Billion |
| Market Size 2032 |
USD 407.9 Billion |
| Compound Annual Growth Rate (CAGR) |
11.40% (2024-2032) |
| Base Year |
2023 |
| Market Forecast Period |
2024-2032 |
| Historical Data |
2019- 2022 |
| Market Forecast Units |
Value (USD Billion) |
| Report Coverage |
Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered |
Diseases, Product,Distribution Channel, and Region |
| Geographies Covered |
North America, Europe, Asia Pacific, and the Rest of the World |
| Countries Covered |
The US, Canada, German, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled |
NuVasive, Spinal Technology, Inc., C H Martin Company, Aspen Medical Products, Lawall Prosthetics and Orthotics, SPINEFORM LLC, Össur, Orthotech, Chaneco, Boston Orthotics & Prosthetics, Charleston Bending Brace, Trulife, DJO, Wilmington Orthotics & Prosthetics, Inc., Horton's Orthotics & Prosthetics, UNYQ, Optec USA, Inc., and Zimmer Biomet Holdings Inc. |
| Key Market Opportunities |
The increased incidence of adult scoliosis due to lifestyle issues such as bad posture, lifestyle changes, and way too much stress to the spine. |
| Key Market Dynamics |
Rising prevalence of scoliosis & musculoskeletal disorders |
Frequently Asked Questions (FAQ) :
The Scoliosis Treatment market size was valued at USD 165.2 Billion in 2023.
The market is projected to grow at a CAGR of 11.40% during the forecast period, 2024-2032.
North America had the largest share in the market
The key players in the market are NuVasive, Spinal Technology, Inc., C H Martin Company, Aspen Medical Products, Lawall Prosthetics and Orthotics, SPINEFORM LLC, Össur, Orthotech.
The cervical thoracic lumbar sacral orthosis (CTLSO)dominated the market in 2022.
The Hospital and Clinics had the largest share in the market.
